Skip to Main Navigation
Skip to Page Content

Testing Status of AZT + Pyrazinamide combination (AIDS Initiative) M930016




  • 30516-87-1 - 3'-Azido-3'-deoxythymidine (AIDS)
  • 30516-87-1 - AZT transplacental carcinogenesis study
  • 98-96-4 - Pyrazinamide

Known Uses

Combination therapeutic agents for use in AIDS therapy

Short-Term Toxicity

  • 13 weeks (Gavage)  (C93003)  Completed 
    • Mice: B6C3F1

Organ Systems Toxicity

  • 30 days Repro/Dev Gen Tox (28-Day) (Gavage)  (RDGT95001)  Completed 
    • NIH Number: 02-4408
      Citation: NIEHS Technical Report on the Reproductive, Developmental, and General Toxicity Study of 3'-Azido-3'-deoxythymidine (AZT) and Pyrazinamide Combinations (CASRNs 30516-87-1 and 98-96-4) Administered by Gavage to Swiss (CD-1®) Mice
    • Male and Female Mice: Swiss
    • Dose: Multiple.